Incheon, South Korea, October 30, 2025 — Celltrion, Inc., a global biopharmaceutical company specializing in biosimilars and innovative biologics, today announced that the U.S. Food and Drug Administration (FDA) has granted interchangeability designations for its denosumab biosimilars STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo). These products correspond respectively to Amgen’s Prolia® and Xgeva®, offering new, interchangeable options for patients in osteoporosis and oncology-related bone loss care. This dual recognition marks the first FDA-approved interchangeable denosumab biosimilars and represents a major step forward for biosimilar competition in the U.S. biologics market.
Science Significance
Denosumab, a monoclonal antibody that inhibits RANK ligand (RANKL), has been a foundational therapy for managing osteoporosis and skeletal-related events associated with cancer metastases. By blocking osteoclast activation, denosumab prevents bone resorption and helps maintain skeletal integrity. Celltrion’s biosimilars — STOBOCLO and OSENVELT — were developed using advanced analytical comparability and clinical studies demonstrating equivalent safety, efficacy, and pharmacokinetics to their reference biologics. The interchangeability designation confirms that patients can be switched from Amgen’s originator products to Celltrion’s biosimilars without any risk of diminished clinical efficacy or increased safety concerns. This scientific milestone validates the maturity of biosimilar science, showcasing how molecular precision and immunogenicity profiling now enable regulators to treat biosimilars with the same confidence as their reference biologics.
Regulatory Significance
The FDA’s decision follows the Biologics Price Competition and Innovation Act (BPCIA) framework, which defines the standards for biosimilar and interchangeable biological products in the United States. Interchangeability status is a higher regulatory bar, allowing automatic substitution at the pharmacy level, similar to generic drugs. With this action, STOBOCLO® and OSENVELT® become the first interchangeable denosumab biosimilars approved under the BPCIA pathway. The designation underscores FDA’s confidence in the totality of evidence approach, combining analytical, preclinical, and clinical data to support equivalence. This development also illustrates how regulators are accelerating biosimilar adoption as a tool for healthcare sustainability, particularly for high-cost biologics. FDA’s decision builds on a series of approvals in 2024–2025 aimed at broadening access to key biologics such as insulin, adalimumab, and trastuzumab.
Business Significance
Advertisement
For Celltrion, these dual approvals represent a commercial and strategic breakthrough in the U.S. market — the world’s largest biologics arena. By gaining interchangeability for both Prolia® and Xgeva® references, the company positions itself as a first-mover in a multi-billion-dollar therapeutic segment. Amgen’s Prolia and Xgeva combined generated over $4 billion in global revenue in 2024, and biosimilar competition could significantly reshape market dynamics. Celltrion’s integrated model — spanning cell-line development, manufacturing, and global distribution — enables rapid scaling and competitive pricing. Furthermore, interchangeability status enhances payer confidence and formulary access. U.S. pharmacy benefit managers (PBMs) and healthcare systems now have the legal and regulatory backing to substitute STOBOCLO and OSENVELT directly, improving affordability and expanding patient reach. This achievement also consolidates Celltrion’s broader biosimilar portfolio, which includes infliximab (Remsima®), trastuzumab (Herzuma®), adalimumab (Yuflyma®), and ustekinumab biosimilars, reinforcing the company’s long-term competitiveness and growth trajectory in North America.
Patients’ Significance
For patients, the FDA’s decision has direct and immediate clinical and economic impact. Osteoporosis affects millions of Americans — primarily postmenopausal women and cancer patients at risk for bone metastases — and biologic therapies such as denosumab can be prohibitively expensive. With STOBOCLO and OSENVELT now interchangeable, patients gain access to equivalent therapy at significantly lower cost, reducing financial barriers to long-term treatment adherence. Moreover, interchangeability ensures continuity of care: patients can switch from Prolia® or Xgeva® to Celltrion’s biosimilars without additional physician intervention, preserving convenience while maintaining therapeutic efficacy. “This designation empowers clinicians and pharmacists to offer affordable options without compromising quality, safety, or outcomes,” said a Celltrion spokesperson. “Our mission is to ensure that cutting-edge biologic therapy is accessible to every patient who needs it.” By expanding availability and lowering cost burdens, these approvals directly contribute to improved bone health outcomes and reduced fracture risk for vulnerable populations.
Policy Significance
From a policy perspective, the FDA’s move represents a major advancement in biosimilar market maturity. It reinforces the agency’s commitment to promoting competition, access, and sustainability in biologics — a sector that continues to strain public and private payer budgets. The approval also aligns with the U.S. Department of Health and Human Services (HHS) and Centers for Medicare & Medicaid Services (CMS) policies encouraging biosimilar substitution to reduce drug spending. With interchangeability in place, stakeholders expect increased price transparency and improved formulary inclusion across both public and private insurance networks. For the broader regulatory ecosystem, the case sets a precedent for dual-product interchangeability designations — an uncommon regulatory pathway demonstrating FDA’s flexibility in evaluating shared molecular identity and indication overlap.
Transaction Highlights
The U.S. FDA has granted interchangeability designations for Celltrion’s STOBOCLO® (denosumab-bmwo), referencing Amgen’s Prolia®, and OSENVELT® (denosumab-bmwo), referencing Xgeva®. These approvals make Celltrion’s biosimilars the first interchangeable denosumab products authorized in the United States. The designations allow pharmacy-level substitution without prescriber intervention, marking a regulatory first for bone-targeted monoclonal antibodies. Both approvals were based on comprehensive comparability studies confirming equivalent safety, efficacy, and immunogenicity profiles to their reference biologics. The decision positions Celltrion to expand U.S. biosimilar market penetration and reinforces FDA’s broader policy goal of fostering competition and reducing biologic costs.
Source: Celltrion Inc. Press Release
